Clinical trial

Constitution of a Collection of Biological Samples With the Aim of Carrying Out Clinico-biological and Physiopathological Investigations of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases

Name
RC31/23/0361
Description
The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.
Trial arms
Trial start
2024-05-06
Estimated PCD
2029-04-01
Trial end
2034-04-01
Status
Recruiting
Treatment
Blood sampling
Blood will be taken in larger quantity
Arms:
Patients suffering from autoimmune, dysimmune or auto-inflammatory dermatological disease
Remainders of samples taken as part of the treatment
blood, CSF, saliva, stools, urine, other biological fluids and tissue biopsies, hair follicles
Arms:
Patients suffering from autoimmune, dysimmune or auto-inflammatory dermatological disease
Size
800
Primary endpoint
Building a collection of biological samples and clinical-biological data from patients with autoimmune, dysimmune or auto-inflammatory dermatological disease
Day 0 and through study completion, an average of 1 year
Eligibility criteria
Inclusion Criteria: Skin damage of documented or probable autoimmune, dysimmune or autoinflammatory origin. The patients included may be adults or children, and will be: * Patients with autoimmune bullous dermatoses (pemphigus, pemphigoid and others), * Patients with systemic autoimmune diseases associated with skin damage (lupus, scleroderma, dermatomyositis for example), * Patients with cutaneous lupus * Patients with dysimmune skin diseases (psoriasis, eczema) * Patients with immuno-induced dermatological disorders or drug dermatitis * Patients receiving, or likely to receive, new, innovative therapies (new molecule on the market, checkpoint inhibitors, gene therapy, cell therapy, etc.). Patients with dermatological damage whose autoimmune, dysimmune or auto-inflammatory origin is suspected Exclusion Criteria: * Patients under protective supervision (guardianship, curators) * Patients under 6 years old * Pregnant or breastfeeding woman
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'blood, CSF, saliva, stool, urine, other body fluids and tissue biopsies, hair follicles'}, 'enrollmentInfo': {'count': 800, 'type': 'ESTIMATED'}}
Updated at
2024-05-09

1 organization

2 products

4 indications

Indication
Skin Diseases